ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1141

Response To H. Pylori Treatment and Autoantibody In Chronic Thrombocytopenia

Mitsuyo Kinjo and Kensuke Nakanishi, Internal Medicine, Okinawa Chubu Hospital, Uruma City Okinawa, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Autoantibodies and thrombocytopenia

  • Tweet
  • Email
  • Print
Session Information

Title: Infection Related Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: Helicobacter pylori (H. pylori) infection has been linked to pathogenesis of autoimmune disease including chronic idiopathic thrombocytopenic purpura (ITP). Prior studies showed platelet counts have improved after eradication of H. pylori in some patients with ITP. To clarify the role of H. pylori in chronic thrombocytopenia and its response to treatment in association with autoantibody status.

Methods: Medical records from 2002-2012 were reviewed at Okinawa Chubu Hospital to locate patients > 18 years old with chronic ITP (platelet < 100,000 /mm3for > 12 months). After exclusion of acute ITP and secondary chronic thrombocytopenia, 49 patients were included. We recorded antinuclear antibody (ANA), antiphospholipid antibody (APLA) and H. pylori status. Treatment for H. pylori infection was administered to patients with positive H. pylori detected by breath test. Platelet count was monitored at least for one year after eradication of H. pylori.

Results: Median age was 44 years (range, 18-86); 39/49 subjects were female (80%). ANA or APLA was positive but H. pylori was negative in 25/49 (50%); H. pylori infection was present in 15/49 (31%), and both H. pylori and autoantibody were positive in 10/49 (20%). All patients with H. pylori infection were treated with antibiotics. Eradication failed to improve platelet counts in 10/10 cases with positive ANA or APLA. Among patients with H. pylori without autoantibodies, 3/5 responded with increased platelet counts and 2/5 did not. The overall rate of positive autoantibody in non-responders was therefore 10/12 (83%), and zero in responders.

Conclusion: Among patients with chronic ITP and H. pylori infection, refractory thrombocytopenia after eradication may identify a subset of patients with positive autoantibody. Immunological response to H. pylori may be associated with poor response rate to antibiotic treatment in patients with concomitant ITP and H. pylori infection.


Disclosure:

M. Kinjo,
None;

K. Nakanishi,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/response-to-h-pylori-treatment-and-autoantibody-in-chronic-thrombocytopenia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology